184 related articles for article (PubMed ID: 7542644)
1. The presence and cytotoxicity of CD16+ CD2- subset from PBL and NK cells in long-term IL-2 cultures enhanced by Prothymosin-alpha.
Cordero OJ; Sarandeses C; López-Rodríguez JL; Nogueira M
Immunopharmacology; 1995 Apr; 29(3):215-23. PubMed ID: 7542644
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-2 killer cells: in vitro evaluation of combination with prothymosin alpha.
López-Rodríguez JL; Cordero OJ; Sarandeses C; Viñuela J; Nogueira M
Lymphokine Cytokine Res; 1994 Jun; 13(3):175-82. PubMed ID: 7948426
[TBL] [Abstract][Full Text] [Related]
3. Differential oncolytic effect of NK-enriched subsets in long-term interleukin-2 cultures.
Fuchshuber PR; Lotzová E
Lymphokine Cytokine Res; 1992 Oct; 11(5):271-6. PubMed ID: 1281676
[TBL] [Abstract][Full Text] [Related]
4. Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens.
Weil-Hillman G; Fisch P; Prieve AF; Sosman JA; Hank JA; Sondel PM
Cancer Res; 1989 Jul; 49(13):3680-8. PubMed ID: 2471587
[TBL] [Abstract][Full Text] [Related]
5. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM
Cancer Res; 1992 Nov; 52(22):6318-22. PubMed ID: 1384959
[TBL] [Abstract][Full Text] [Related]
6. Long-term cultures of human peripheral blood lymphocytes with recombinant human interleukin-2 generate a population of virtually pure CD3+ CD16- CD56- large granular lymphocyte LAK cells.
Roussel E; Gerrard JM; Greenberg AH
Clin Exp Immunol; 1990 Nov; 82(2):416-21. PubMed ID: 1700746
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-2-activated killer cell activity in colorectal tumor patients: evaluation of in vitro effects by prothymosin alpha1.
Eckert K; Grünberg E; Immenschuh P; Garbin F; Kreuser ED; Maurer HR
J Cancer Res Clin Oncol; 1997; 123(8):420-8. PubMed ID: 9292704
[TBL] [Abstract][Full Text] [Related]
8. Prothymosin alpha enhances human natural killer cell cytotoxicity: role in mediating signals for NK activity.
Cordero OJ; Sarandeses CS; López JL; Nogueira M
Lymphokine Cytokine Res; 1992 Oct; 11(5):277-85. PubMed ID: 1467368
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity, growth, and phenotype of long-term IL-2 cultures of human NK and T lymphocytes.
Fuchshuber PR; Lotzová E; Pollock RE
Lymphokine Cytokine Res; 1991 Apr; 10(1-2):51-9. PubMed ID: 1651770
[TBL] [Abstract][Full Text] [Related]
10. NK and LAK activities from human marrow progenitors. I. The effects of interleukin-2 and interleukin-1.
Keever CA; Pekle K; Gazzola MV; Collins NH; Gillio A
Cell Immunol; 1990 Mar; 126(1):211-26. PubMed ID: 1689220
[TBL] [Abstract][Full Text] [Related]
11. Human lymphokine-activated killer cells are cytotoxic against cells infected with Toxoplasma gondii.
Subauste CS; Dawson L; Remington JS
J Exp Med; 1992 Dec; 176(6):1511-9. PubMed ID: 1460415
[TBL] [Abstract][Full Text] [Related]
12. Induction of lymphokine-activated killer activity in mice by prothymosin alpha.
Baxevanis CN; Gritzapis AD; Dedoussis GV; Papadopoulos NG; Tsolas O; Papamichail M
Cancer Immunol Immunother; 1994 Apr; 38(4):281-6. PubMed ID: 8168124
[TBL] [Abstract][Full Text] [Related]
13. Coexpression of Fc gamma receptor IIIA and interleukin-2 receptor beta chain by a subset of human CD3+/CD8+/CD11b+ lymphocytes.
Zupo S; Azzoni L; Massara R; D'Amato A; Perussia B; Ferrarini M
J Clin Immunol; 1993 May; 13(3):228-36. PubMed ID: 7686565
[TBL] [Abstract][Full Text] [Related]
14. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
[TBL] [Abstract][Full Text] [Related]
15. In vitro responsiveness to interleukins and theophylline of CD16+, CD56- natural killer cells in a patient with chronic granular lymphocyte disorder.
Bayle C; Vitté-Mony I; Lang P; Pico J; Hercend T; Bertoglio J
Leukemia; 1992 May; 6(5):470-6. PubMed ID: 1375700
[TBL] [Abstract][Full Text] [Related]
16. Antibodies to adhesion molecules inhibit the lytic function of MHC-unrestricted cytotoxic cells by preventing their activation.
Zarcone D; Viale O; Cerruti G; Tenca C; Malorni W; Arancia G; Iosi F; Galandrini R; Velardi A; Moretta A
Cell Immunol; 1992 Sep; 143(2):389-404. PubMed ID: 1380897
[TBL] [Abstract][Full Text] [Related]
17. Increased proliferation, lytic activity, and purity of human natural killer cells cocultured with mitogen-activated feeder cells.
Rabinowich H; Sedlmayr P; Herberman RB; Whiteside TL
Cell Immunol; 1991 Jul; 135(2):454-70. PubMed ID: 1709827
[TBL] [Abstract][Full Text] [Related]
18. CD16- CD56+ natural killer cells after bone marrow transplantation.
Jacobs R; Stoll M; Stratmann G; Leo R; Link H; Schmidt RE
Blood; 1992 Jun; 79(12):3239-44. PubMed ID: 1375847
[TBL] [Abstract][Full Text] [Related]
19. Definition of a natural killer NKR-P1A+/CD56-/CD16- functionally immature human NK cell subset that differentiates in vitro in the presence of interleukin 12.
Bennett IM; Zatsepina O; Zamai L; Azzoni L; Mikheeva T; Perussia B
J Exp Med; 1996 Nov; 184(5):1845-56. PubMed ID: 8920872
[TBL] [Abstract][Full Text] [Related]
20. Expression of an early myelopoietic antigen (CD33) on a subset of human umbilical cord blood-derived natural killer cells.
Handgretinger R; Schäfer HJ; Baur F; Frank D; Ottenlinger C; Bühring HJ; Niethammer D
Immunol Lett; 1993 Aug; 37(2-3):223-8. PubMed ID: 7505004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
